OSI Pharmaceuticals News
Most Popular OSI Pharmaceuticals Story
Tarceva successful as maintenance therapy
Genentech and OSI Pharmaceuticals today announced that a global phase III study of Tarceva--dubbed Saturn--met the primary endpoint of progression-free survival. The study, conducted by Roche,... Read more...
Latest Headlines
- November 7, 2008
- May 15, 2008
- October 2, 2007
- November 6, 2006
- July 27, 2006
- November 10, 2005
- September 11, 2005
- August 31, 2005
- August 21, 2005
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
